Efficacy of once daily human GLP-1 analogue, Liraglutide on dietary lifestyle and treatment satisfaction in type 2 diabetic patients.

Efficacy of once daily human GLP-1 analogue, Liraglutide on dietary lifestyle and treatment satisfaction in type 2 diabetic patients. - Efficacy of Liraglutide on dietary lifestyle and treatment satisfaction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010614

Enrollment

100

Registered

2013-05-01

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Liraglutide Other diabetes standard oral treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients who continue to visit to trial site for the treatment Treated by diet & exercise therapy or diet & exercise therapy with oral anti-diabetic agents more than 3 months

Exclusion criteria

Exclusion criteria: Contraindication of Liraglutide Comorbidity of endocrine disease except diabetes. Existence of severe diabetic complication like diabetic nephropathy severer than grade III by criteria of Japan Diabetes Society and diabetic retinopathy severer than by criteria of Japan Diabetes Society.

Design outcomes

Primary

Measure	Time frame
Change in total calorie intake Change in component of food (Protein, Fat, Carbohydrate) Treatment satisfaction	—

Secondary

Measure	Time frame
Change in HbA1c Change in weight and BMI Adverse events.	—

Countries

Japan

Contacts

Public ContactKoichiro Yasuda

Osaka Saiseikai Noe Hospital Department of diabetes and endocrinology

kyasuda@noe.saiseikai.or.jp06-6932-0401

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026